Current Drug Development and Therapeutic Insight of Breast Cancer Treatment

Pratiksha S. Behare*, Sakshi V. Patil, Dipali S. Chaudhari, Devesh P. Bhavsar Akanksha B. Pardhi

Khandesh Education Society's Late Shri. Pandharinath Chhagansheth Bhandarkar College of D. Pharmacy & Late Prof R. K. Kele College of B. Pharmacy, Amalner- 425401 Dist-Jalgaon (M.S.) India

Correspondence: beharepratiksha15@gmail.com

­­­

INTRODUCTION

The most common cancer in women and a leading cause of cancer-related death for women globally is breast cancer. It accounts for 28.2% of all cancers in Indian women and is the largest cause of cancer-related deaths among women in the US and India. Breast cancer accounts for almost 30% of all newly diagnosed malignancies in women each year. An estimated 310,720 women will receive an invasive breast cancer diagnosis in 2024. Women under 50 will make up 16% of this group. Additionally, ductal carcinoma in situ will be diagnosed in 56,500 women. As people age, their chance of getting breast cancer rises, reaching its highest between the ages of 50 and 64. One kind of cancer that begins in the breast is called breast cancer. It may begin in one or both of them. When cells start to proliferate uncontrollably, cancer begins. Different regions of the breast might become the site of breast cancer. The upper ribs and chest muscles support the breast, an organ. Each of a woman's two breasts, which are primarily glands, ducts, and fatty tissue, produces and delivers milk to feed neonates and infants. When cancer cells enter the bloodstream or lymphatic system and travel to other areas of the body, breast cancer can spread. Breast cancer comes in a variety of forms, including ductal carcinoma, which begins in the breast's ducts. Lobular carcinoma: The glands that produce breast milk are called lobules.  Inflammatory breast cancer: This uncommon, aggressive form of the disease makes the breast appear swollen because cancer cells obstruct lymphatic arteries. The darker skin surrounding the nipple and the nipple itself are affected by this type of breast illness.The most prevalent kind of breast cancer that is not invasive is called ductal carcinoma in situ. Invasive breast cancer and lobular carcinoma in situ are two examples. It spreads beyond the lobules or breast ducts. breast cancer cells that lack HER 2 protein, progesterone, or oestrogen receptors; invasive ductal carcinoma; and triple-negative breast cancer. LuminaB: A higher grade, worse prognosis tired breast cancer that's FR positive & has high ki 62 expression. HR - Positive breast cancer. The literature mentions many Causes of breast cancer but the most important fact we must know is that breast cancer is always caused by DNA damage of cell, & other such as History, Personal health history and Sex, age, family. Breast cancer can cures  by mainy treatments,The main treatments for breast cancer includes Surgery, Chemotherapy, radiotherapy , targated therapy and nanotechnology. Precision drug delivery, early disease detection, and cutting-edge medical therapies are all made possible by nanotechnology, which has an impact on human health. It improves efficacy and minimises negative effects by targeting particular cells.

HISTORY

In 1959 Richard Feynman, a physicist, presented a Concept for manipulating atoms & molecules individually.Research & work on nanotechnology in india Started in 2001 with formation of nanoscience tchnology inti initiative with intial funding of RS-60 cro The ancient indian medical system, Ayurveda, used nanoparticle - based medicines gold nanoparticles to treat aliments.Nanotechnology has been effective in breast cancer treatment and is Considerd strategy to Conventional a promising overcome the limitations therapies. Materials of many kinds were created at the nanoscale level by nanotechnology. Particulate materials, which have at least one dimension less than 100 nm, are included in the broad class of materials known as nanoparticles. Depending on their size, shape, and chemical characteristics, Nonoparticles creates materials that fall into a number of categories, including metal nanoparticles, ceramics, semiconductors, polymers, lipid nanoparticles, and carbon-based nanoparticles.

NANOTECHNOLOGY:

According to the American Society for Testing and Materials, nanotechnology uses nanoparticles, which are tiny particles of matter that range in size from 1 to 100 nm in two or three dimensions. Applications of nanobiotechnology are referred to as biomedcall. Within the rapidly evolving field of nanotechnology, the nanobiotechnology system is characterized as nano-sized. They have given rise to a new field called nanoocology and can facilitate significant advancements in the diagnosis, treatment, and detection of human tumors. The development of nonoparticles for targeted medication administration, biomolecular profiling of cancer biomarkers, and in vivo tumor imaging is ongoing. Polymeric, lipid, organic, protein, carbon, and synthetic nanoparticles all hold promise for addressing contemporary therapy issues such as medication resistance and harm to healthy tissue. By enhancing medication, nanotechnology is transforming the treatment of breast cancer.

MECHANISM OF NANOPARTICLE IN BREAST CANCER:

One essential feature of nano-carriers for drug delivery is their ability to preferentially target cancer cells, which improves therapeutic efficacy while shielding healthy cells from damage. The targeting design of NPbased medications has been the subject of numerous investigations. It is essential to first comprehend tumor biology and the relationship between nano-carriers and tumor cells in order to effectively address the difficulties associated with tumor targeting and the creation of nano-carrier systems. The two main categories of targeting mechanisms are active targeting and passive targeting.

ACTIVE TARGETING:

Through directed interactions between ligands and receptors, active targeting focuses on cancer cells in particular. By targeting the molecules that are overexpressed on the surface of cancer cells, the ligands on the surface of NPs are able to differentiate between the targeted and healthy cells. Therapeutic medications can be successfully released from internalized NPs through receptor-mediated endocytosis, which is triggered by the contact between irgands on NPs and receptors on the surface of cancer cells. As a result, active targeting works especially well for macromolecules like proteins and SiRNAs that are used in medication delivery. Among the different kinds of targeting moieties are peptides, amino acids, vitamins, carbohydrates, and monoclonal antibodies. Transferri receptors, folate receptors, glycoproteins, and the epidermal layer are among the extensively studied receptors that these ligands selectively bind to on targeted cell.

PASSIVE TARGETING:

Passive targeting in nanoparticle-mediated drug delivery leverages the unique characteristics of tumors to enhance the effectiveness of therapeutic agents. This approach often utilizes the Enhanced Permeability and Retention (EPR) effect, where tumor blood vessels are more permeable due to larger gaps between endothelial cells. As a result, nanoparticles can accumulate in the tumor microenvironment. The EPR effect is particularly beneficial for nanoparticles sized between 10 to 100 nanometers, enabling them to evade quick clearance by the kidneys, thereby maximizing drug delivery to tumors while reducing overall toxicity.

CLASSIFICATION OF NANOPARTICLES

LIPID BASED NANOPARTICLE:

Eg.phospholipid

In 1963, Alec Bangham discovered the drug delivery mechanism known as liposomes. They are made up of phospholipids dispersed in water. They consist of a phospholipid shell with a nonpolar hydrophobic tail and a polar hydrophilic head. Liposomes can be classified as zwitterionic, positively charged, negatively charged, or uncharged based on their charge. Negatively charged lipids, such as phosphatidic acid and phosphatidylserine, and positively charged lipids, such as DOTMA(1-(2,3-dioleyloxy)propyl)N,N,N-triethyl ammonium)  and DOTAP, contribute to the stability and efficacy of drugs. In addition, the stability and fluidity of liposomes depend on cholesterol, which can be modified to improve targeting to cancer cells. Drugs that are poorly soluble in water can be made more soluble with liposomes. Liposomes are used in the treatment of breast cancer by several methods. Passive targeting allows liposomes to enter the tumor through leaky vasculature caused by disordered endothelial cells. Active targeting involves modifying liposomes with specific antibodies or ligands to engage specific receptors on cancer cells, although this is limited to tumors with certain antigens.Liposomes can encapsulate both hydrophilic and hydrophobic compounds, with hydrophobic drugs sandwiched between the two layers and water-soluble drugs in the core. Surface modifications help deliver higher drug concentrations to tumor sites, while the phospholipid bilayer protects the payload from degradation before reaching the tumor. Overall, liposomes show promise in the treatment of breast cancer, reducing side effects and protecting healthy tissues.

POLYMERIC BASED NANOPARTICLES:

Eg. Hyaluronic acid with paclitaxel (PLGA polymer)

By putting PTX in PLGA (polylactic-co-glycolic acid) and then coating it with HA (HA-PTX-PLGA), Cerqueira and colleagues created a unique formulation using a modified oil-in-water emulsion technique that dynamically targets triple-negative breast cancer. To illustrate the release of PTX from HA-PTX-PLGA and HA-uncoated NPs (PTX-PLGA), an in vitro release study was conducted using MDA-MB-231 cells. Comparing HA-PTX-PLGA NPs to PTX-PLGA, it was shown that the latter reduced the cytotoxicity of PTX in the malignant cell. Additionally, PTX from HAcoated NPs was better absorbed by cells, indicating that the interaction between HA and CD44 led to the receptor-facilitated endocytosis. Additionally, the hemolytic property was evaluated to make sure that intravenous (i.v.) administration would not result in any problems. I

INORGANIC BASED NANOPARTICLES:

Eg.gold nanopaticles

Gold nanoparticles can vary in size, shape, and structure, and researchers have developed a number of formulations for different medicinal uses.The spherical structures known as gold nanoshells (AuNSs) are made of a thin coating of gold with a silica core and range in size from 50 to 150 nm. Their optical properties can be changed by varying the core diameter and shell thickness. Gold nanorods (AuNRs) are made from chloroauric acid and can be shaped using a gold tool to create spheres, shells, rods, and cages of various sizes.

PROTEIN BASED NANOPARTICLES:

Eg.albumin

Recently, protein-based nanosystems, especially albumin nanoparticles, have attracted much attention because albumins are of natural origin and have several desirable properties such as biodegradability, biocompatibility, non-immunogenicity, high drug binding capacity, biostability, low toxicity, and a turnover time of about 19 days. They are more convenient for surface modification due to the presence of carboxylic and amino groups. Studies have shown that albumin nanoparticles can effectively encapsulate and deliver various chemotherapeutic agents, including small molecules, proteins, and nucleic acids, to the target site in the body. They aid in the digestion and transport of hydrophobic long-chain fatty acids. The development of albumin-based nanocarriers for drug delivery is attractive due to the various binding sites that facilitate the incorporation of hydrophilic and hydrophobic drugs into the particle matrix. The most commonly used preparation method is ethanol dissolution. To increase the stability of the final nanostructure, a cross-linking agent, such as glutaraldehyde, is usually used. The higher concentration of albumin in the blood than in the interstitial compartments allows the diffusion of albumin to tumor sites. In addition, several albumin receptors, namely gp60 and SPARC, are overexpressed in cancer cells, which may help to further enhance the uptake of albumin-based fillers into cancer sites.

CARBON BASED NANOPARTICLE:

Eg.Carbon nanotube

Carbon nanotubes (CNTs) are carbon-based materials featuring a hexagonal structure, available as singlewalled (SWNT) or multi-walled (MWNT) varieties, with SWNTs being smaller. They can be produced using methods like arc discharge and chemical vapor deposition. CNTs possess properties that make them valuable in materials science and biomedicine, especially their ability to enter cells with low toxicity. However, their insolubility in solvents, particularly water, poses challenges, which functionalization with biopolymers aims to overcome. The text highlights CNTs' potential in cancer therapy, focusing on two drug delivery strategies: forming non-covalent drug complexes and stable covalent binding. CNTs can selectively damage cancer cells using strong optical absorption in the near-infrared range while sparing healthy tissue. Studies show that heating CNTs within cancer cells can cause cell death when paired with near-infrared or radiofrequency irradiation. Biocompatibility is typically achieved through non-covalent functionalization, often utilizing phospholipid–polyethylene glycol chains for targeting cancer-specific receptors. CNTs are also used in phototherapy for breast cancer after being modified with antibodies that recognize specific markers. The pyrene linker aids in binding these antibodies to CNTs due to strong interactions of their aromatic surfaces. While this functionalization shows good stability, further investigations are needed to evaluate its effectiveness in living systems and the release of therapeutic biomolecules. To prevent interference with proteins, CNTs are coated with polyethylene glycol, enabling selective binding to target receptors and inducing cell death upon infrared activation. This strategy combines the thermal effects of CNTs with targeted delivery, offering potential benefits for cancer treatment, although limitations with near-infrared light must still be addressed.

HYBRID BASED NANOTECHNOLOGY:

A hybrid nanoparticle (HNP) system, made up of two or more materials, excipients, or both, is created in order to get beyond the limitations of individual nanocarriers. These systems lessen the drawbacks of individual nanocarriers while combining their benefits. HNPs are a kind of core-shell nanoparticle; the therapeutic cargo is encapsulated in the core, while the shell can be created by coating or functionalizing the core with various substances to accomplish active targeting. The most widely utilized polymers for the production of HNPs are chitosan (CHI), polycaprolactone (PCL), polylactic acid (PLA), and poly (lactic-co-glycolic acid) (PLGA). These polymers are biocompatible and biodegradable, and the USFDA has previously approved a small number of them. In vitro, hybrid systems have demonstrated superiority in cytotoxicity, cellular uptake, loading efficiency, and release kinetics.

LIMITATIONS OF CURRENT TREATMENT:

Existing therapeutic strategies have several shortcomings in the treatment of breast cancer, including lack of selective toxicity, which leads to decreased therapeutic efficacy and, consequently, impaired medical diagnosis; damage to healthy tissues and, therefore, reduced doses of anticancer drugs are usually administered to minimize toxicity to normal tissues; poor biodistribution and drug penetration into solid tumors; heterogeneous vasculature at tumor sites increases drug extravasation. Current treatments tend to deposit more drugs in normal internal organs (10-20 times more) than in a comparably loaded tumor area, and many chemotherapeutic agents are unable to penetrate blood vessels larger than 40-50 mm (equivalent to the combined diameter of three to five cells) which can lead to multidrug resistance (MDR) and ultimately treatment failure. Furthermore, the development of MDR in tumor cells after treatment with an anticancer molecule can generate resistance to a variety of drugs through the overexpression of drug efflux proteins.

RISK FACTORS AND PRECAUTIONS FOR BREAST CANCER:

The absolute probability of acquiring BC is influenced by some known risk factors. Risk factors that can be changed include eating a balanced diet, exercising frequently, and consuming alcohol in moderation. One significant risk factor for BC is the cumulative exposure of breast tissue to estrogen. By restricting the use of hormonal birth control pills, avoiding hormone replacement treatment, and having their first child before the age of 30, they can reduce this risk. Younger age at menarche and older age at natural menopause are nonmodifiable risk variables that raise cumulative exposure to estrogen. Known mutations in high-penetrant BC genes like BRCA1 and BRCA2, the cumulative interaction of risk-associated alleles of BC susceptibility SNPs, and/or family history are examples of non-modifiable genetic risk factors.

TOXICITY OF NANOPARTICLES:

Nanoparticle toxicity and difficulties in the clinical management of breast cancer: Only a small number of medications have been approved for clinical trials, despite the fact that a large variety of nanoparticles with various ions and surface changes have been developed and tested preclinically. Systemic adverse effects, such as nausea, drowsiness, irritability, stomach pain, allergic responses, inflammation, and dyskinesia, might result with repeated dosages. The fundamental components, size, shape, and functional groups adorning the surface of nanoparticles are the primary determinants of their toxicity. Smaller nanoparticles have no trouble diffusing into healthy cells and interacting with proteins, polysaccharides, and nucleic acids. Metal nanoparticles frequently cause oxidative stress and the production of reactive oxygen species (ROS), which harm all healthy cellular components and cause cell death. Additionally, Al2O3, CuO, Fe3O4, NiO, TiO2, and ZnO NPs can also cause apoptosis and cell cycle arrest. Additionally, compared to negatively charged NPs, positively charged NPs are more cytotoxic. The cytotoxicity of NPs in healthy cells is also significantly influenced by their form. For example, Fe2O3 NPs with a rod shape are more cytotoxic than those with a spherical shape. The source of the toxicity is still mostly unknown, despite the fact that many researchers have verified the toxicity of various NPs. Furthermore, since the investment in sophisticated manufacturing techniques and adherence to regulatory standards always brings increasing costs, the cost of creating and implementing nanoparticle-based medicines cannot be neglected.According to studies, the cost of producing nanoparticle formulations can be up to ten times greater than that of traditional treatments, which can severely limit patient access. Before receiving clinical approval, NPs’ shortand long-term toxicities as well as their pharmacokinetic and pharmacodynamic outcomes should be evaluated.

FUTURE PROSPECTIVE:

Due to their relative simplicity of manufacturing, globular NPs have historically been employed for tumour targeting; still, a number of recent studies indicate that non-spherical NPs, similar as rods, discs, components, and ellipsoids, may be more successful for targeting BC. further thorough exploration including cell attachment and reticuloendothelial system clearing is also needed in order to make a establishment determination regarding the ideal NP shape. probing BC-applicable ligands and receptors in systems that offer a precise representation of in vivo figure, structure, and rheology is necessary. NPs may be readily acclimatized to enter and treat BC more efficiently by taking into account their shape in addition to their size and substance.The use of medicine combinations, which are patient-specific and reliant on time and cure, is a harmonious approach for all types of medicine treatment. NP- intermediatedco-delivery of multiple treatments has led to the possibility of integrating Al with nanomedicine for optimisation in synergistic nanotherapy. Advanced BC opinion and treatment is one of the areas of wisdom, drug, and nanotechnology that AI is revolutionising; this area primarily focusses on clinical images and curatives in relation to tumour size, shape, intensity, and texture, which together affect in further thorough tumour characterisation. Al- directed nano- robots can directly pinpoint the medicine action at the bone target point through the shadowing sensor.In the near future, Al might help with nanomedicine exploration to identify possible cancer treatments as well as to diagnose the cancer’s stage. The use of Al in nanomedicine will be a implicit option in the future, despite the fact that oncological exploration has formerly seen remarkable success with nanomedicine.

CONCLUSION:

Breast cancer remains a significant global health challenge, with its prevalence increasing due to genetic, environmental, and lifestyle factors. Conventional treatments like surgery, chemotherapy, and radiotherapy have limitations, including poor targeting and high toxicity. Nanotechnology offers a promising solution by enhancing precision in drug delivery, minimizing side effects, and improving treatment efficacy through active and passive targeting mechanisms. Nanoparticles—such as lipid-based, polymeric, inorganic, protein-based, carbon-based, and hybrid systems—enable selective drug delivery to tumor sites while sparing healthy tissues.

Despite its potential, nanotechnology also poses challenges, including toxicity, high production costs, and the need for further research on long-term effects. Future advancements may involve AI-driven nanomedicine for more personalized, efficient treatment strategies, leveraging nanorobots and machine learning for early detection and therapy optimization. While nanotechnology in breast cancer treatment is still evolving, it holds immense potential to revolutionize oncology, offering hope for more effective, less invasive, and patient-specific cancer therapies.

REFERENCE:

 [1] About Breast cancer.American cancer society.1-13

[2] Fanfair D,Desai S,Kelty C.The early history of nanotechnology.connexions module 2007., 2

[3] Roco M.C. Nanoparticles and Nanotechnology research.Journal of nanoparticle research,1.1999.2

[4] Khan I . Nanoparticles:properties,applicationsand toxicities.Arabian journal of chemistry 2019.909-910

[5] Gaberial A.Introduction to nanotechnology and its application to medicine.surg neurol2004,216-217

[6] Yezhelyev m.v, Gao X, Xing Y, Haji A.Al, Nie 5,0 'Regan R.m, Emerging use of nanoparticles in diagonsis and treatment of breast cancer", Lancet oncol 2006, 7. 657

[7] " Yoo Y, Zhou y, liu L, Xu y. Chen Q, Wang y, wu shijie, Deng Y, Zhang J, Shao A. Nanoparticle – Based Drug Delivery in cancer Therapy. and Its Role in Overcoming Drug Resistance frontiers In molecular Biosciences, 20 ,2020,  5

[8] Oechler J.B, Rajapraksha w. Albrech H, "Emerging Applications of Nanoparticles in the Diagnosis and Treatment Breast cancer", Journal of Personalized medicine, 7.

[9] Ochler J.B. Rajapaksha w., Albrech H, "Emerging Applications of Nanoparticles in the Treatment Breast cancer",Journel of Personalized medicine , 2024, 2

[10] chaudhari A, Kumar D.N. Shaik R.A. Eid B.G, Abdel - Nai'm A.B. My shudab, Ahmad A. Agrawal A.K, "Lipid Based Nanoparticles a Pivotul delivery Approach in Triple negative Breast cancer (TBNC) Therapy ,International Journal of Molecular Sciences, 2022,7-8.

[11] Ali S, Z Qizilbash, FF, Anna Md, S Alhakamy, N.A. Baboota, 5. Ali, 1. Iblymuric  . Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations,MDPI.2021,6

[12] Lee J., chatterjee D, Lee M., Krinchnan S Gold .nanoparticles in breast cancer treatment". promise and potential pitfalls, NIH Public Access ,Aug 2024,2

[13] Solanki R., Rajput P., Jodha B., Yadav U., patel s., enhancing apoptosis mediated anticancer activity of evodianine through protein-based nanoparticles in breast cancer cells, nature portfolio 2024, 14, 2

[14] Bianco A, Kastorelos K, Prato M., "Opportunitiesande hallenges of carbon-based nanomaterials for cancer therapy. Expert Opinion Drug Delivery, 2008, 332- 333

[15] Rajana M., Aare M., Padakanti S., Valamla B., Urati A, khatri D., Sigh S., Mehra M., Multifuncional hybrid nanoparticles in diagnosis & therapy of breast cancer, Journal of controlled release, Dec 2022, 352, 2

[16] Grewal I., singh s, Arora s., sharme N, polymeric nanoparticles for breast cancer Therapy! A comprehensive review, Biointerface Research in applied chemistry 2021, 11, 11153

[17] Erin zaluzec, Lorenzo S., systemic and Local Steratergies for primary prevention of Breast cancer, Cancers 2024, 16, 1-2

[18] Kumar G., Yan w, fei G, Deng L, Jiapeng C., Targeting engineemed nanoparticles for Breast cancer Therapy, pharmaceutics, 2021, 13, 21 & 22